

1. Original Articles

1. Sakai D, **Matsumiya W (corresponding author)**, Kusuhara S, Nakamura M. Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia. *J Ophthalmic Inflamm Infect*. 2021 Jun 14;11(1):17.
2. Kim KW, Kusuhara S, Katsuyama-Yoshikawa A, Nobuyoshi S, Kitamura M, Mori S, Sotani N, Ueda K, **Matsumiya W**, Miki A, Kurimoto T, Imai H, Nakamura M. Changes in Gene Expression Profiling and Phenotype in Aged Multidrug Resistance Protein 4-Deficient Mouse Retinas. *Antioxidants (Basel)*. 2021 Mar 15;10(3):455. doi: 10.3390/antiox10030455.
3. Nishisho R, Kusuhara S, Sotani N, Kim KW, Katsuyama-Yoshikawa A, **Matsumiya W**, Akashi K, Morinobu A, Nakamura M. Changes in choroidal imaging parameters following adalimumab therapy for refractory noninfectious uveitis. *Graefes Arch Clin Exp Ophthalmol*. 2021 Jan 7. doi: 10.1007/s00417-020-05032-9. Online ahead of print.
4. Hayashida M, Miki A, Nakai S, **Matsumiya W**, Imai H, Kusuhara S, Nakamura M. Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity. *PLoS One*. 2020 Oct 12;15(10):e0240557. doi: 10.1371/journal.pone.0240557. eCollection 2020.
5. Kurimoto T, Ueda K, Mori S, Kamada S, Sakamoto M, Yamada-Nakanishi Y, **Matsumiya W**, Nakamura M. A Single-Arm, Prospective, Exploratory Study to Preliminarily Test Effectiveness and Safety of Skin Electrical Stimulation for Leber Hereditary Optic Neuropathy. *J Clin Med*. 2020 May 6;9(5):1359. doi: 10.3390/jcm9051359.
6. Katsuyama A, Kusuhara S, Asahara SI, Nakai SI, Mori S, **Matsumiya W**, Miki A, Kurimoto T, Imai H, Kido Y, Ogawa W, Nakamura M. En face slab optical coherence tomography imaging successfully monitors progressive degenerative changes in the innermost layer of the diabetic retina. *BMJ Open Diabetes Res Care*. 2020 Mar;8(1):e001120.
7. Tetsumoto A, Imai H, Hayashida M, Otsuka K, **Matsumiya W**, Miki A, Nakamura M. The comparison of the surgical outcome of 27-gauge pars plana vitrectomy for primary rhegmatogenous retinal detachment between air and SF6 gas tamponade. *Eye (Lond)*. 2020 Feb;34(2):299-306.
8. Katsuyama A, Kusuhara S, Awano H, Nagase H, **Matsumiya W**, Nakamura M. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl. *BMC Ophthalmol*. 2019 Aug 13;19(1):179. doi: 10.1186/s12886-019-1192-0.
9. Tetsumoto A, Imai H, Otsuka K, **Matsumiya W**, Miki A, Nakamura M. Clinical factors contributing to postoperative aqueous flare intensity after 27-gauge pars plana vitrectomy for the primary rhegmatogenous retinal detachment. *Jpn J Ophthalmol*. 2019 May 18. doi:

10.1007/s10384-019-00672-9.

10. Katsuyama A, Kusuhara S, Nishisho R, **Matsumiya W**, Azumi A, Nakamura M. Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behçet's disease. *Clin Ophthalmol*. 2019 Mar 20;13:521-527.
11. Nakai S, **Matsumiya W** (corresponding author), Keiko O, Miki A, Nakamura M, Honda S. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. *Jpn J Ophthalmol*. 2019 Jan;63(1):100-108.
12. Nagano C, Nozu K, Yamamura T, Minamikawa S, Fujimura J, Sakakibara N, Nakanishi K, Horinouchi T, Iwafuchi Y, Kusuhara S, **Matsumiya W**, Yoshikawa N, Iijima K. TGFBI-associated corneal dystrophy and nephropathy: a novel syndrome? *CEN Case Rep*. 2018 Aug 7. doi: 10.1007/s13730-018-0356-8.
13. Kusuhara S, Katsuyama A, **Matsumiya W**, Nakamura M. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma. *Graefes Arch Clin Exp Ophthalmol*. 2018 Apr;256(4):809-814. doi: 10.1007/s00417-018-3933-9. Epub 2018 Feb 21.
14. Sugiyama A, Sakurada Y, Honda S, Miki A, **Matsumiya W**, Yoneyama S, Kikushima W, Iijima H. Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab. *Ophthalmologica*. 2018;239(1):52-59.
15. Yamashiro K, Mori K, Honda S, Kano M, Yanagi Y, Obana A, Sakurada Y, Sato T, Nagai Y, Hikichi T, Kataoka Y, Hara C, Koyama Y, Koizumi H, Yoshikawa M, Miyake M, Nakata I, Tsuchihashi T, Horie-Inoue K, **Matsumiya W**, Ogasawara M, Obata R, Yoneyama S, Matsumoto H, Ohnaka M, Kitamei H, Sayanagi K, Ooto S, Tamura H, Oishi A, Kabasawa S, Ueyama K, Miki A, Kondo N, Bessho H, Saito M, Takahashi H, Tan X, Azuma K, Kikushima W, Mukai R, Ohira A, Gomi F, Miyata K, Takahashi K, Kishi S, Iijima H, Sekiryu T, Iida T, Awata T, Inoue S, Yamada R, Matsuda F, Tsujikawa A, Negi A, Yoneya S, Iwata T, Yoshimura N. A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration. *Sci Rep*. 2017 Aug 23;7(1):9196.
16. Nakai S, Honda S, **Matsumiya W**, Miki A, Nakamura M. ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration. *Mol Vis*. 2017 Jul 26;23:514-519.
17. Nakai S, Honda S, Miki A, **Matsumiya W**, Nakamura M. Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy. *Ophthalmologica*. 2017;237(3):123-127.
18. **Matsumiya W**, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. *Graefes Arch Clin Exp*

Ophthalmol. 2017;255(3):541-548.

19. Enomoto H, Miki A, **Matsumiya W**, Honda S. Ophthalmologica. 2015;234(3):135-8.
Evaluation of Oxygen Supplementation Status as a Risk Factor Associated with the Development of Severe Retinopathy of Prematurity.
20. **Matsumiya W**, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M. Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up. Ophthalmologica. 2015;234(1):33-9.
21. Ueda K, **Matsumiya W (corresponding author)**, Otsuka K, Maeda Y, Nagai T, Nakamura M. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol. 2015 Jun 6;15:58.
22. Yanagisawa S, Sakurada Y, Miki A, **Matsumiya W**, Imoto I, Honda S. The association of elastin gene variants with two angiographic subtypes of polypoidal choroidal vasculopathy. PLoS One. 2015 Mar 16;10(3):e0120643.
23. Hirose M, **Matsumiya W**, Honda S, Nakamura M. Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion. Clin Ophthalmol. 2014 Nov 19;8:2301-5.
24. Kusuhara S, **Matsumiya W**, Imai H, Honda S, Tsukahara Y, Negi A. Evaluating dissociated optic nerve fiber layer appearance using en face layer imaging produced by optical coherence tomography. Ophthalmologica. 2014;232(3):170-8.
25. Tagami M, **Matsumiya W**, Imai H, Kusuhara S, Honda S, Azumi A. Autologous antibodies to outer retina in acute zonal occult outer retinopathy. Jpn J Ophthalmol. 2014 Nov;58(6):462-72.
26. Honda S, Miki A, Yanagisawa S, **Matsumiya W**, Nagai T, Tsukahara Y. Comparison of the outcomes of photodynamic therapy between two angiographic subtypes of polypoidal choroidal vasculopathy. Ophthalmologica. 2014;232(2):92-6.
27. **Matsumiya W**, Honda S, Yanagisawa S, Miki A, Nagai T, Tsukahara Y. Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics. 2014 Apr;15(6):833-43.
28. **Matsumiya W**, Honda S, Kusuhara S, Tsukahara Y, Negi A. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. BMC Ophthalmol. 2013 Apr 4;13:10.
29. **Matsumiya W**, Kusuhara S, Shimoyama T, Honda S, Tsukahara Y, Negi A. Predictive value of preoperative optical coherence tomography for visual outcome following macular hole surgery: effects of imaging alignment. Jpn J Ophthalmol. 2013 May;57(3):308-15.

30. **Matsumiya W**, Kusuhara S, Hayashibe K, Maruyama K, Kusuhara H, Tagami M, Schuetz JD, Negi A. Forskolin modifies retinal vascular development in Mrp4-knockout mice. *Invest Ophthalmol Vis Sci*. 2012 Dec 7;53(13):8029-35.
31. Yanagisawa S, Kondo N, Miki A, **Matsumiya W**, Kusuhara S, Tsukahara Y, Honda S, Negi A. Difference between age-related macular degeneration and polypoidal choroidal vasculopathy in the hereditary contribution of the A69S variant of the age-related maculopathy susceptibility 2 gene (ARMS2). *Mol Vis*. 2011;17:3574-82.
32. Yanagisawa S, Kondo N, Miki A, **Matsumiya W**, Kusuhara S, Tsukahara Y, Honda S, Negi A. A common complement C3 variant is associated with protection against wet age-related macular degeneration in a Japanese population. *PLoS One*. 2011;6(12):e28847.
33. Kishimoto H, Kusuhara S, **Matsumiya W**, Nagai T, Negi A. Retinal surface imaging provided by Cirrus high-definition optical coherence tomography prominently visualizes a dissociated optic nerve fiber layer appearance after macular hole surgery. *Int Ophthalmol*. 2011 Oct;31(5):385-92.
34. **Matsumiya W**, Honda S, Bessho H, Kusuhara S, Tsukahara Y, Negi A. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. *J Ophthalmol*. 2011;2011:742020.
35. Matsuo M, Honda S, **Matsumiya W**, Kusuhara S, Tsukahara Y, Negi A. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization. *Eur J Ophthalmol*. 2012 Mar-Apr;22(2):210-5.

II. Case Reports

1. **Matsumiya W**, Karaca I, Ghoraba H, Akhavanrezayat A, Mobasserian A, Hassan M, Regenold J, Yasar C, Liedtke M, Kitazawa K, Nguyen QD. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. *Am J Ophthalmol Case Rep*. 2021 Jun 9;23:101133.
2. Kim KW, Kusuhara S, Tachihara M, Mimura C, **Matsumiya W**, Nakamura M. A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer. *Am J Ophthalmol Case Rep*. 2021 Mar 12;22:101072. doi: 10.1016/j.ajoc.2021.101072.
3. Pham BH, Hien DL, **Matsumiya W**, Tuong Ngoc TT, Doan HL, Akhavanrezayat A, Yaşar Ç, Nguyen HV, Halim MS, Nguyen QD. Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema. *Am J Ophthalmol Case Rep*. 2020 Aug 20;20:100881. doi: 10.1016/j.ajoc.2020.100881.
4. Sakai D, **Matsumiya W**(corresponding author), Kusuhara S, Nakamura M. The choroidal structure changes in a case with hypertensive choroidopathy. *Am J Ophthalmol Case Rep*. 2020;18:100710. Published 2020 Apr 13. doi:10.1016/j.ajoc.2020.100710

5. Jain A, Chea S, **Matsumiya W**, Halim MS, Yaşar Ç, Kuang G, Sepah YJ, Khanani AM, Do DV, Nguyen QD. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. *Am J Ophthalmol Case Rep*. 2020 Apr 2;18:100687. doi: 10.1016/j.ajoc.2020.100687.
6. **Matsumiya W**, Kusahara S, Yamada Y, Azumi A, Negi A. Sweet's syndrome with panuveitis resembling Behçet's disease. *Jpn J Ophthalmol*. 2012 May;56(3):268-72.
7. **Matsumiya W**, Honda S, Imai H, Kusahara S, Tsukahara Y, Negi A. A Case of Bilateral Macular Holes Showing Onset and Spontaneous Closure over Very Short Intervals. *Case Rep Ophthalmol*. 2010 Sep 13;1(2):47-52.

III. Review

1. Honda S, **Matsumiya W**, Negi A. Polypoidal choroidal vasculopathy: clinical features and genetic predisposition. *Ophthalmologica*. 2014;231(2):59-74.